Phosphate compounds, a process for their preparation and pharmaceutical compositions containing them

1. A phosphate compound of formula (I):

wherein:

X and Y represent a carbon atom or a nitrogen atom, wherein X and Y may not simultaneously represent two carbons atoms or two nitrogen atoms;

A 1 and A 2 , together with the atoms carrying them, form an optionally substituted, aromatic or non-aromatic heterocycle Het composed of 5, 6 or 7 ring members which may have, in addition to the nitrogen represented by X or by Y, from one to 3 heteroatoms selected independently from oxygen, sulphur and nitrogen, wherein the nitrogen atom may be substituted by a hydrogen atom, a linear or branched (C 1 C 6 )alkyl group or a —C(O)—O -Alk group wherein Alk is a linear or branched (C 1 C 6 alkyl group,

or A 1 and A 2 independently of one another represent a hydrogen atom, a linear or branched (C 1 -C 6 )polyhaloalkyl, a linear or branched (C 1 -C 6 )alkyl group or a cycloalkyl;

T represents a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl group optionally substituted by from one to three halogen atoms, a (C 1 -C 4 )alkyl-NR 1 R 2 group, or a (C 1 -C 4 )alkyl-OR 6 group;

R 1 and R 2 independently of one another represent a hydrogen atom or a linear or branched (C 1 C 6 )alkyl group, or R 1 and R 2 together with the nitrogen atom carrying them from a heterocycloalkyl;

R 3 represents a linear or branched (C 1 -C 6 )alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, a cycloalkyl group, a (C 3 -C 10 )cycloalkyl-(C 1 -C 6 )alkyl group wherein the alkyl moiety is linear or branched, a heterocycloalkyl group, an aryl group or a heteroaryl group, wherein one or more of the carbon atoms of the preceding groups, or of their possible substituents, may be deuterated;

R 4 represents an aryl group, a heteroaryl group, a cycloalkyl group or a linear or branched (C 1 -C 6 )alkyl group, wherein one or more of the carbon atoms of the preceding groups, or of their possible substituents, may he deuterated;

R 5 represents a hydrogen atom, a halogen atom, a linear or branched (C 1 C 6 )aikyl group, or a linear or branched (C 1 -C 6 )alkyl group:

R 6 represents a hydrogen atom or a linear or branched (C 1 -C 6 )alkenyl group;

R a , R b , R c and R d , each independently of the others, represent, a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl, a linear or branched (C 2 -C 6 )alkenyl, a linear or branched (C 2 -C 6 )alkynyl, an aryl, a heteroaryl, a halogen atom, a linear or branched (C 1 -C 6 )alkoxy group, a hydroxyl group, a linear or branched (C 1 -C 6 )polyhaloalkyl group, a trifluoromethoxy group, —NR 7 R 7 ′, nitro, R 7 —CO—(C 0 -C 6 )alkyl-, R 7 —CO—NH—(C 0 -C 5 )alkyl-, NR 7 R 7 ′—CO—(C 0 -C 6 )alkyl-, NR 7 R 7 ′—CO—(C 0 -C 6 )alkyl-O—, R 7 —SO 2 —NH—(C 0 -C 6 )alkyl-, R 7 —NH—CO—NH—(C 0 -C 6 )alkyl-, R 7 —O—CO—NH—(C 0 -C 6 )alkyl-, a heterocycloalkyl group, or the substituents of one of the pairs (R a , R b ), (R b ,R c ) or (R c ,R d ) together with the carbon atoms carrying them form a ring composed of from 5 to 7 ring members, which ring may have from one to 2 hetero atoms selected from oxygen and sulphur, wherein one or more carbon atoms of the ring defined hereinbefore may be deuterated or substituted by from one to 3 groups selected from halogen and linear or branched (C 1 -C 6 )alkyl;

R 7 and R 7 ′independently of one another represent a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl, a linear or branched (C 2 -C 6 )alkenyl, a linear or branched (C 2 -C 6 )alkynyl, an aryl or a heteroaryl, or R 7 and R 7 ′ together with nitrogen atom carrying them form a heteroaryle composed of from 5 to 7 ring members,

wherein at least one a the carbon atoms of the compound of formula (I) substituted by one of the following phosphate groups: —OPO(OM)(OM′), —OPO(OM)(O − M 1 + ), —OPO(O −M 1 + )(O −M 2 + ), —OPO(O − )(O − )M 3 2+ , —OPO(OM)(O[CH 2 CH 2 O] n CH 3 ), or —OPO(O −M 1 30 )(O[CH 2 CH 2 O] H CH 3 ) wherein M and M′ independently of one another represent a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 ) alkynyl group, a cycloalkyl or a heterocycloalkyl both composed of 5 or 6 ring members, and wherein M 1 30 and M 2 + independently of one another represent a pharmaceutically acceptable monovalent cation, and M 3 2+ represents a pharmaceutically acceptable divalent cation and n is an integer from 1 to 5,

it being understood that:

“aryl” means a phenyl, naphthyl biphenyl or indenvl group,

“hetcroaryl” means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 4 hetero atoms selected from oxygen, sulphur and nitrogen (including quaternary nitrogens),

“cycloalkyl” means any mono- or bi-cyclic, non-aromatic, carboeyclic group containing, from 3 to 10 ring members,

“heterocycloalkyr” means any mono- or bi-cyclic, non-aromatic, condensed or spiro group composed of 3 to 10 ring members and containing from 1 to 3 hetero atoms selected from oxygen, sulphur, SO, SO 2 and nitrogen,

wherein the aryl, heteroaryl, cycloalkyl aand heterocycloalkyl groups so defined and the groups alkyl, alkenyl, alkynyl and alkoxy may be optionally substituted by from 1 to 3 groups selected from optionally substituted, linear or branched (C 1 -C 6 )alkyl, (C 3 -C 6 )spiro, linear or branched, optionally substituted (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkyl-S-, hydroxy oxo (or N-oxide where appropriate), nitro, cyano, —COOR′ , —OCOR′ , NR′R″ ,linear or branched (C 1 -C 6 )polyhaloalkyl, trifluoromethoxy, (C 1 -C 6 )alkylsulphonyl, halogen, optionally substituted aryl, heteroaryl, aryloxy, arylthio, cycloalkyl, heterocycloalkyl optionally substituted by one or more halogen atoms or alkyl groups, wherein R′ and R″ independently of one another represent a hydrogen atom or an optionally substituted, linear or branched (C 1 -C 6 )alkyl group,

wherein the Het group defined in formula (I) may be optionally substituted by from one to three groups selected from linear or branched (C 1 -C 6 )alkyl, hydroxy, linear or branched (C 1 -C 6 )alkoxy. NR 1 ′R 1 ″ and halogen, wherein R 1 ′and R 1 ″independently of one another represent a hydrogen atom or an optionally substituted, linear or branched (C 1 -C 6 )alkyl group,

or an enantiomerhr, a diastereoisomer, or an addition salt thereof with a pharmaceutically acceptable acid or base.

2. The compound according to claim 1 , wherein R 4 represents phenyl substituted in the para position by a group of formula —OPO(OM)(OM′), —OPO(OM)(O − M 1 + ), —OPO(O − M 1 + )(O − M 2 + ), —OPO(O − )(O − )M 3 2+ , —OPO(OM)(O[CH 2 CH 2 O] n CH 3 ), or —OPO(O −M 1 + )(O[CH 2 CH 2 O] n CH 3 ), wherein M and M′ independently of one another represent a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, a cycloalkyl or a heterocycloalkyl both composed of 5 or 6 ring members, and wherein M 1 + and M 2 + independently of one another represent a pharmaceutically acceptable monovalent cation, and M 3 2+ represents a pharmaceutically acceptable divalent cation and n is an integer from 1 to 5, wherein the phenyl group may optionally be substituted by one or more halogen atoms.

3. The compound according to claim 1 , wherein R 4 represents phenyl substituted in the para position by a group of formula —OPO(O − Na + )(O − Na + ).

4. The compound according to claim 1 , wherein X represents a carbon atom and Y represents a nitrogen atom.

5. The compound according to claim 1 , wherein the group:

represents a 5,6,7,8-tetrahydroindolizine, an indolizine or a dimethylated pyrrole,

6. The compound according to claim 1 , wherein T represents a methyl, (morpholin-4-yl)methyl or 3-(morpholin-4-yl)propyl group.

7. The compound according to claim 1 , wherein R a and R d each represent a hydrogen atom and (R b , R c ) , together with the carbon atoms carrying them, form a 1,3dioxolane group or a 1,4-dioxane group; or R a , R c and R d each represent a hydrogen atom and R b represents a hydrogen atom or a halogen atom.

8. The compound according to claim 1 , wherein R a and R d each represent a hydrogen atom, R b represents a halogen atom and R, represents a methoxy group.

9. The compound according to claim 1 , wherein R a , R b and R d each represent a hydrogen atom and R c represents a NR 7 R 7 ′—CO—(C 0 -C 6 )alkyl-O-group.

10. The compound according to claim 1 , wherein R 3 represents a group selected from phenyl, 1H-indoie, 1H-pyrrolo [2,3 -b]pyridine, pyridine, 1H-pyrazole, 1H -pyrrole and 2,3-dihydro-1H-pyrrolo[2,3b]pyridine, those groups optionally having one or more substituents selected from linear or branched (C 1 C 6 alkyl, cyano and trideuteriomethyl.

11. The compound according to claim 1 , which is selected from:

4-[{[3-(6-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H) -yl]carbonyl}-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydroindolizin-1-yl]carbonyl}(phenyl)amino]phenyl disodium phosphate,

4-[{[5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H) -yl]carbonyl}phenyl)-1,2-dimethyl-1H-pyrrol-3-yl]carbonyl}(pyridin-4-yl)amino]phenyl disodium phosphate,

4-({[5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H) -yl]carbonyl}phenyl)-1,2-dimethyl-1H-pyrrol-3-yl]carbonyl}[1-(trideuteriomethyl) -1H-pyrazol-4-yl]amino)phenyl disodium phosphate,

4-[{[5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H) -yl]carbonyl}phenyl)-1,2-dimethyl-1H-pyrrol-3-yl]carbonyl}(5-cyano-1,2-dimethyl -1H-pyrrol-3-yl)amino]phenyl disodium phosphate,

4-[{[5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H) -yl]carbonyl}phenyl)-1,2-dimethyl-1H-pyrrol-3-yl]carbonyl}(5-cyano-1-methyl-1H -pyrrol-3-yl)amino]phenyl disodium phosphate,

4-[{[5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H) -yl]carbonyl}phenyl)-1,2-dimethyl-1H-pyrrol-3-yl]carbonyl}(5-cyano-1-methyl-1H -pyrrol-3-yl)amino]phenyl disodium phosphate,

4-[(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl){[5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-1,2-dimethyl-1H -pyrrol-3-yl]carbonyl}amino]phenyl disodium phosphate, and

4-[{[5-(5-fluoro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H) -yl]carbonyl}phenyl)-1,2-dimethyl-1H-pyrrol-3-yl]carbonyl}(1-methyl-1H -pyrazol-4-yl)amino]phenyl disodium phosphate,

or an enantiomer, a diastereoisomer, or an addition salt thereof with a pharmaceutically acceptable acid or base.

12. A pharmaceutical composition comprising the compound according to claim 1 in combination with one or more pharmaceutically acceptable excipients.

13. A composition comprising the compound according to claim 1 in combination with an anti-cancer agent selected from genotoxic agents, mitotic poisons, anti-metabolites, proteasome inhibitors, kinase inhibitors and antibodies.

14. The composition according to claim 13 further comprising one or more pharmaceutically acceptable excipients.

15. A combination comprising the compound according to claim 1 and an anticancer agent selected from genotoxic agents, mitotic poisons, anti-metabolites, proteasome inhibitors, kinase inhibitors and antibodies.